Avadel Pharmaceuticals plc (NASDAQ: AVDL) is -20.54% lower on its value in year-to-date trading and has touched a low of $10.41 and a high of $19.09 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AVDL stock was last observed hovering at around $11.66 in the last trading session, with the day’s loss setting it -0.44%.
Currently trading at $11.22, the stock is -14.93% and -14.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.06 million and changing -3.77% at the moment leaves the stock -25.80% off its SMA200. AVDL registered -2.09% loss for a year compared to 6-month loss of -27.57%. The firm has a 50-day simple moving average (SMA 50) of $13.1972 and a 200-day simple moving average (SMA200) of $15.1381.
The stock witnessed a -12.89% gain in the last 1 month and extending the period to 3 months gives it a -28.99%, and is 4.71% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.06% over the week and 6.61% over the month.
Avadel Pharmaceuticals plc (AVDL) has around 154 employees, a market worth around $1.08B and $138.16M in sales. Fwd P/E is 20.68. Profit margin for the company is -52.53%. Distance from 52-week low is 7.78% and -41.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-65.79%).
The EPS is expected to grow by 76.06% this year.
Avadel Pharmaceuticals plc (AVDL) Top Institutional Holders
231.0 institutions hold shares in Avadel Pharmaceuticals plc (AVDL), with institutional investors hold 84.08% of the company’s shares. The shares outstanding are 89.83M, and float is at 88.18M with Short Float at 10.71%. Institutions hold 80.07% of the Float.
The top institutional shareholder in the company is VIVO CAPITAL, LLC with over 3.97 million shares valued at $55.85 million. The investor’s holdings represent 4.332% of the AVDL Shares outstanding. As of 2024-06-30, the second largest holder is TRI LOCUM PARTNERS LP with 1.19 million shares valued at $16.72 million to account for 1.2973 of the shares outstanding. The other top investors are BIOIMPACT CAPITAL LLC which holds 0.78 million shares representing 0.8542% and valued at over $11.01 million, while KNOLL CAPITAL MANAGEMENT, LLC holds 0.6544 of the shares totaling 0.6 million with a market value of $8.44 million.
Avadel Pharmaceuticals plc (AVDL) Insider Activity
The most recent transaction is an insider purchase by MCHUGH THOMAS S, the company’s Chief Financial Officer. SEC filings show that MCHUGH THOMAS S bought 2,000 shares of the company’s common stock on Jan 16 ’24 at a price of $14.50 per share for a total of $29000.0. Following the purchase, the insider now owns 80500.0 shares.
Avadel Pharmaceuticals plc disclosed in a document filed with the SEC on Dec 28 ’23 that McCamish Mark Anthony (Director) sold a total of 75,000 shares of the company’s common stock. The trade occurred on Dec 28 ’23 and was made at $14.53 per share for $1.09 million. Following the transaction, the insider now directly holds 67025.0 shares of the AVDL stock.
